Secondary therapy, metastatic progression, and cancer-specific mortality in men with clinically high-risk prostate cancer treated with radical prostatectomy. - Wikidata - wikimedia - TriplyDB

Secondary therapy, metastatic progression, and cancer-specific mortality in men with clinically high-risk prostate cancer treated with radical prostatectomy.

Secondary therapy, metastatic progression, and cancer-specific mortality in men with clinically high-risk prostate cancer treated with radical prostatectomy.

http://www.wikidata.org/entity/Q37086821

about

Risk assessment for prostate cancer metastasis and mortality at the time of diagnosis Extended lymph node dissection in robotic radical prostatectomy: Current status Detection of Lymph Node Metastases with SERRS Nanoparticles.What are the outcomes of radical prostatectomy for high-risk prostate cancer?High-risk prostate cancer in the United States, 1990-2007 Current status of radical prostatectomy for high-risk prostate cancer.Role of robot-assisted radical prostatectomy in the management of high-risk prostate cancer Temporal trends and predictors of pelvic lymph node dissection in open or minimally invasive radical prostatectomy.Long-term survival after radical prostatectomy versus external-beam radiotherapy for patients with high-risk prostate cancer Surgery for high-risk localized prostate cancer.Oncologic outcomes of surgery in t3 prostate cancer: experience of a single tertiary center Ultrasonic Nanobubbles Carrying Anti-PSMA Nanobody: Construction and Application in Prostate Cancer-Targeted Imaging.High-risk prostate cancer-classification and therapy.Oncologic Outcome of Radical Prostatectomy as Monotherapy for Men with High-risk Prostate Cancer.Metastasis after radical prostatectomy or external beam radiotherapy for patients with clinically localized prostate cancer: a comparison of clinical cohorts adjusted for case mix Very High-Risk Localized Prostate Cancer: Outcomes Following Definitive Radiation.Trends in radical prostatectomy.Impact of stage migration and practice changes on high-risk prostate cancer: results from patients treated with radical prostatectomy over the last two decades.An audit of referral and treatment patterns of high-risk prostate cancer patients in Alberta.Combined brachytherapy and external beam radiotherapy without adjuvant androgen deprivation therapy for high-risk prostate cancer.Multimodal treatment for high-risk prostate cancer with high-dose intensity-modulated radiation therapy preceded or not by radical prostatectomy, concurrent intensified-dose docetaxel and long-term androgen deprivation therapy: results of a prospect Additional therapy for high-risk prostate cancer treated with surgery: what is the evidence?Outcome of surgery in locally advanced pT3a prostate cancer.Very-high-risk localized prostate cancer: definition and outcomes.Can we improve the definition of high-risk, hormone naïve, non-metastatic prostate cancer?The status of surgery in the management of high-risk prostate cancer.The role for surgery in high-risk prostate cancer.New surgical approaches for clinically high-risk or metastatic prostate cancer.Neoadjuvant Treatment of High-Risk, Clinically Localized Prostate Cancer Prior to Radical Prostatectomy.Increasing use of radical prostatectomy for locally advanced prostate cancer in the USA and Germany: a comparative population-based study.Safety of selective nerve sparing in high risk prostate cancer during robot-assisted radical prostatectomy.Use of the cell cycle progression (CCP) score for predicting systemic disease and response to radiation of biochemical recurrence.The number of risk factors is the strongest predictor of prostate cancer mortality: multi-institutional outcomes of an extreme-risk prostate cancer cohort.Neoadjuvant luteinizing-hormone-releasing hormone agonist plus low-dose estramustine phosphate improves prostate-specific antigen-free survival in high-risk prostate cancer patients: a propensity score-matched analysis.Outcomes of Gleason Score ≤ 8 among high risk prostate cancer treated with 125I low dose rate brachytherapy based multimodal therapy.Preferences in the management of high-risk prostate cancer among urologists in Europe: results of a web-based survey.Matching tumor risk with aggressiveness of treatment in men with multiple comorbidities and early-stage prostate cancer.Cancer-specific mortality of high-risk prostate cancer after carbon-ion radiotherapy plus long-term androgen deprivation therapy.Overall survival of high-risk prostate cancer patients who received neoadjuvant chemohormonal therapy followed by radical prostatectomy at a single institution.Patched 1 Expression Correlates with Biochemical Relapse in High-Risk Prostate Cancer Patients.

P2860

Q24645292-AC722AFD-5437-4B50-9F95-C45907479BF3 Q26749073-F936FF88-23D9-406B-96BE-A169A8D5AB9F Q30373357-012D7ED8-EF75-4B1B-8672-A221E2AD0B50 Q33927594-9B962850-652A-4AD4-8BE9-2AA49CBD2285 Q34168382-6BE1D8FD-F24B-4AFE-B755-A1F5BEDAC82E Q34346841-FC17325A-2774-4190-840A-B485F84BC91F Q34453371-4FF1B098-0FC4-40EE-86DE-B91B33F618E8 Q35106328-8146B811-28F5-45AC-AAA0-0671A37BB3D5 Q35115736-AF841E13-8F1D-4AA7-A96E-2588EBCDFA5A Q35220192-C1E26083-5B80-48CC-8261-4EFFA34339E4 Q35642310-5312CD83-7C4F-4E55-B00F-0F023A39FA9B Q35674555-D8F2968F-DED0-4EA4-B485-BD0466ECEF5D Q35869811-2D9BD4C3-FE58-4BD1-AAAA-087BAB96B2E0 Q37014814-EC2A4FED-CDB0-4AC0-9059-13F246EA6F2F Q37065578-9009CF57-EB11-44BB-A494-25CCE4BB2D64 Q37342181-E6AA8ADC-A0F5-476D-9008-FA55EDD9D967 Q37381775-2527A5F9-529F-44ED-A94D-D7C84B558B51 Q37509084-C02E9F87-1A3B-4808-8D69-F1B22BC4B5B9 Q37515889-E241B162-80A3-457D-9757-ED1D881BE759 Q37523651-B2B03044-A0D5-4A0A-879B-A1BEB6F0391A Q37528968-603A3CF8-D04C-4790-9CEF-F4CBCEDA655C Q37546041-EF53DBD4-32F5-4E00-8EB6-9EE2B213CDC8 Q37579084-0AC3BEFF-B2A3-4BB4-94EE-7AFC23AEB080 Q37623723-212E5A69-B8CD-4941-99BA-39E0568BEC1E Q38151298-43BE9787-EAE7-47F3-94E6-27032BAB61C0 Q38211115-BB0B841D-27C3-4A9E-A340-E1155A7EEE4F Q38591851-D6159BCC-B57A-44A8-B6E6-EFB45EBFEA7F Q38598269-180DC995-984C-46AA-8495-6728CDAF5911 Q38770371-1A350844-01C6-4C5A-89D7-B409D6DEC674 Q39400229-F5F72649-CFD3-4D9E-AD6E-DCA6FD6B6BC6 Q39583603-2DDD1AED-C712-448C-BB30-8949FDF9BE5D Q39675735-12150977-FDA6-4864-A481-338EA4FB86E1 Q40967893-573FAD96-E562-4C65-AFFD-A8050A15D2EF Q41436143-4A9403FC-29E7-422B-85D0-4B749A160029 Q41955736-B828A45C-A4A4-4614-AB99-47F3794037DF Q42659138-3804AA0F-D32A-432E-AD53-71E1D23F079A Q46066104-6F84E119-8D45-4796-BF7E-5EE308C65473 Q47100168-500ECA25-2F80-4704-8170-B0F00BE14D0D Q47329081-66BEA97C-98EA-455C-B9AD-5100AC25A027 Q47562519-524A2CC9-9967-403F-8B11-936642E4C1C0

P2860

Secondary therapy, metastatic progression, and cancer-specific mortality in men with clinically high-risk prostate cancer treated with radical prostatectomy.

http://www.wikidata.org/entity/Q37086821

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on 12 October 2007

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

Secondary therapy, metastatic ...... ed with radical prostatectomy.

@en

Secondary therapy, metastatic ...... ed with radical prostatectomy.

@nl

type

label

Secondary therapy, metastatic ...... ed with radical prostatectomy.

@en

Secondary therapy, metastatic ...... ed with radical prostatectomy.

@nl

prefLabel

Secondary therapy, metastatic ...... ed with radical prostatectomy.

@en

Secondary therapy, metastatic ...... ed with radical prostatectomy.

@nl

P1433

Q37086821-30916D04-8F1E-46F4-BF1A-FBBB59B07AC4

P1476

Q37086821-E124FA2D-2663-4913-AC87-414BDA701A5F

P2093

Q37086821-2FF8690E-8C94-4E49-9BA1-CB6F75A0FEA1

Q37086821-71C4D244-1EB9-444D-94C6-41E7E8A5AAD8

Q37086821-76178A05-1E04-4C23-A862-A614B54CE29E

Q37086821-7933E67C-A122-457C-A0A5-8D6202EE2E58

Q37086821-B7717D9C-D4F1-4AB8-BC16-4CA923260E59

Q37086821-CE556BBD-5A96-4224-9B3F-248710410341

Q37086821-F717916F-DA6B-420D-B28C-EDE482203850

P2860

Q37086821-01CC68BE-C8F3-4899-B652-78C6FC19FDEE

Q37086821-01EF9D5D-BA53-4284-BA1E-CD073B977102

Q37086821-19C1EE45-F12C-42D9-97C5-2A325A4B6E8F

Q37086821-389ADE34-9A16-4021-A997-843997EA7AD0

Q37086821-3EA9644A-378E-448F-9EC2-6F1D1F947A0E

Q37086821-536AAA9D-D1F8-4F41-A815-7D4F090DE147

Q37086821-55B1901A-CF38-42D1-833C-3A3A11BD99BA

Q37086821-729D7D87-2EB0-4E37-81DA-6031CCDF2A62

Q37086821-72B7D0B1-96DA-4BF4-9B03-753B82D38D7E

Q37086821-76D46323-41D3-46EB-8FF9-7627052495B3

P304

Q37086821-9EF79A0D-8610-4E42-BEE2-D13FF4906A12

P31

Q37086821-C888854E-092D-4DC6-8503-C41D6679C960

P356

Q37086821-AA87056D-0877-4377-B0E3-4F71388A1A77

P407

Q37086821-3492B8A8-63A4-4FEF-8E26-0DC8D109325C

P433

Q37086821-A6C31161-E182-4A1A-BA74-0602A2AEEDBD

P478

Q37086821-8A19A34F-5ECF-4238-B44D-9626692546EB

P577

Q37086821-D49C0330-BD0D-4F46-B67B-65BF26FDEE3D

P5875

Q37086821-F542798B-6633-49BB-84E9-83260B4082BA

P698

Q37086821-AA166584-A574-4A73-AC7B-05E17D90309A

P932

Q37086821-1A67F5AA-ABAA-4EBF-A0F1-35EBBAE42D1F

P356

J.EURURO.2007.10.008

P1433

European Urology

P1476

Secondary therapy, metastatic ...... ed with radical prostatectomy.

@en

P2093

Angel M Serio

http://www.w3.org/2001/XMLSchema#string

Brett S Carver

http://www.w3.org/2001/XMLSchema#string

Fernando J Bianco

http://www.w3.org/2001/XMLSchema#string

James A Eastham

http://www.w3.org/2001/XMLSchema#string

Ofer Yossepowitch

http://www.w3.org/2001/XMLSchema#string

Peter T Scardino

http://www.w3.org/2001/XMLSchema#string

Scott E Eggener

http://www.w3.org/2001/XMLSchema#string

P2860

Metabolic syndrome in men with prostate cancer undergoing long-term androgen-deprivation therapy

Predictors of secondary cancer treatment in patients receiving local therapy for prostate cancer: data from cancer of the prostate strategic urologic research endeavor.

Long-term outcome of high dose intensity modulated radiation therapy for patients with clinically localized prostate cancer.

Preoperative PSA velocity and the risk of death from prostate cancer after radical prostatectomy.

National practice patterns and time trends in androgen ablation for localized prostate cancer.

Preoperative neoadjuvant androgen withdrawal therapy in prostate cancer: the Canadian experience.

Timing of biochemical failure and distant metastatic disease for low-, intermediate-, and high-risk prostate cancer after radiotherapy.

High-risk localized prostate cancer: a case for early chemotherapy.

Preoperative nomogram predicting the 10-year probability of prostate cancer recurrence after radical prostatectomy

Natural history of biochemical recurrence after radical prostatectomy: risk assessment for secondary therapy.

P304

950-959

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1016/J.EURURO.2007.10.008

http://www.w3.org/2001/XMLSchema#string

P407

P433

5

http://www.w3.org/2001/XMLSchema#string

P478

53

http://www.w3.org/2001/XMLSchema#string

P577

2007-10-12T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

5894250

http://www.w3.org/2001/XMLSchema#string

P698

17950521

http://www.w3.org/2001/XMLSchema#string

P932

2637146

http://www.w3.org/2001/XMLSchema#string